Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3993

Sort by

Sort Order Select

Journal Articles

Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

Blood blood.2025028790.

https://doi.org/10.1182/blood.2025028790

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma

Blood (2025) 146 (2): 155–166.

https://doi.org/10.1182/blood.2024027109

Published: 2025

Includes: Supplemental data

Journal Articles

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Blood (2025) 146 (2): 167–177.

https://doi.org/10.1182/blood.2024026216

Published: 2025

Includes: Supplemental data

Journal Articles

Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysis

Saarang R. Deshpande, Hemza Tarawneh, Chloe Deitelzweig, Jiayi Tong, Ting Zhou, Yong Chen, Adam Cuker

Blood (2025) 146 (2): 233–246.

https://doi.org/10.1182/blood.2025028416

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world data provide a CARbon copy for ide-cel

Timothy Schmidt

Blood (2025) 146 (2): 131–133.

https://doi.org/10.1182/blood.2025029274

Published: 2025

Journal Articles

Reshaping the TME to enhance checkpoint blockade in ENKTL

Annika Dechow, Till Braun

Blood (2025) 146 (2): 129–131.

https://doi.org/10.1182/blood.2025028917

Published: 2025

Journal Articles

Marstacimab Prophylaxis in Hemophilia A/B Without Inhibitors: Results from the Phase 3 BASIS Trial

Davide Matino, Andrew Palladino, Carrie Turich Taylor, Eunhee Hwang, Sangeeta Raje, Satyaprakash Nayak, Regina McDonald, Suchitra Acharya, Johnny Mahlangu, Victor Jiménez-Yuste, Nirmalkumar G Choraria, Dr., Renchi Yang, Chi-kong Li, Murtadha Al-Khabori, Yasser Ahmed Mohamed Soliman Wali, Javier De Jesus Morales-Adrian, Young-Shil Park, Osman Bülent Zülfikar, John Teeter

Blood blood.2024027468.

https://doi.org/10.1182/blood.2024027468

Published: 2025

Includes: Supplemental data

Journal Articles

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Aurore Perrot, Cyrille Touzeau, Jerome Lambert, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Martine Escoffre Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean-Marc Schiano, Mourad Tiab, Mohamad Mohty, Frederique Kuhnowski, Jean Fontan, Salomon Manier, Frederique Orsini-Piocelle, Laure Vincent, Sophie Rigaudeau, Xavier Leleu, Benjamin Hebraud, Laurent Flet, Jean-Valere Malfuson, Caroline Jacquet, Driss Chaoui, Nathalie Meuleman, Wajed Abarah, Lydia Montes, Riad Benramdane, Cecile Sonntag, Hacene Zerazhi, Alina Danu, Olivier Allangba, Mamoun Dib, Murielle Roussel, Sophie Cereja, Julien Depaus, Nicolas Branche, Helene Demarquette, Valentine Richez, Brieuc Cherel, Laurent Frenzel, Marie-Christiane Vekemans, Noemie Bigot, Herve Avet-Loiseau, Jill Corre, Philippe Moreau

Blood (2025) 146 (1): 52–61.

https://doi.org/10.1182/blood.2024026230

Published: 2025

Journal Articles

DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera

Ghaith Abu-Zeinah, Katie Erdos, Neville Lee, Yara Ganom, Christoph Klade, Kurt Krejcy, Heinz Gisslinger, Richard T. Silver, Joseph M. Scandura

Blood (2025) 146 (1): 123–126.

https://doi.org/10.1182/blood.2024027528

Published: 2025

Includes: Supplemental data

Journal Articles

A controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafil

Ibrahim M. Idris, Aminu A. Yusuf, Ismail I. Ismail, Awwal M. Borodo, Mustapha S. Hikima, Shehu A. Kana, Tukur Aliyu, Kabiru Musangedu, Atiku Umar Jibrilla, Sani A. Aji, Aisha Kuliya-Gwarzo, Kabir Mohammad, Jamil A. Galadanci, Rukayya Alkassim, Mohammad A. Suwaid, Nafiu Hussaini, Mark Rodeghier, Arthur L. Burnett, Michael R. DeBaun

Blood (2025) 145 (26): 3101–3112.

https://doi.org/10.1182/blood.2024027898

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia

Zhen Gao, Hong Pan, Lele Zhang, Weiwang Li, Ruonan Li, Jingyu Zhao, Yuechen Luo, Yu Lian, Xiao Yu, Zhexiang Kuang, Neng Nie, Jianping Li, Jinbo Huang, Xin Zhao, Yuan Li, Liwei Fang, Meili Ge, Yizhou Zheng, Jun Shi

Blood (2025) 145 (26): 3189–3193.

https://doi.org/10.1182/blood.2025029006

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical significance of preleukemic somatic GATA1 mutations in children with Down syndrome

Natalina Elliott, Neha Bhatnagar, Gemma Buck, David Cruz Hernandez, Kelly Perkins, Adam J. de Smith, Amélie Chaussade, Nizery Laure, Marlen Metzner, Garnett Catherine, Alice Norton, Kennedy Alison, Triya Chakravorty, Dylan Zhao, Lars Hanssen, Georgina W. Hall, Paresh Vyas, Irene Roberts

Blood blood.2025029250.

https://doi.org/10.1182/blood.2025029250

Published: 2025

Includes: Supplemental data

Journal Articles

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Blood (2025) 145 (25): 3007–3014.

https://doi.org/10.1182/blood.2024026455

Published: 2025

Includes: Supplemental data

Journal Articles

Beyond genotype: challenges in predicting disease risk for carriers of biallelic perforin variants

Blood (2025) 145 (25): 2992–3006.

https://doi.org/10.1182/blood.2024027954

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status

Ciara L. Freeman, Srimathi Srinivasan, Brendan Hodkinson, Sanjay Deshpande, Todd Henninger, Merrill Boyle, Michael L. Wang, Martin Dreyling, David W. Scott

Blood (2025) 145 (25): 3052–3056.

https://doi.org/10.1182/blood.2024026003

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study

Guy Young, Kaan Kavakli, Robert Klamroth, Tadashi Matsushita, Flora Peyvandi, Steven W. Pipe, Savita Rangarajan, Ming-Ching Shen, Alok Srivastava, Jing Sun, Huyen Tran, Chur-Woo You, Bülent Zülfikar, Laurel A. Menapace, Chuanwu Zhang, Yuqian Shen, Marja Puurunen, Marek Demissie, Gili Kenet

Blood (2025) 145 (25): 2966–2977.

https://doi.org/10.1182/blood.2024027008

Published: 2025

Includes: Supplemental data

Journal Articles

Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia

Blood (2025) 145 (25): 3041–3051.

https://doi.org/10.1182/blood.2024027543

Published: 2025

Includes: Supplemental data

Journal Articles

TP53 -mutated acute myeloid leukemia: how can we improve outcomes?

David A. Sallman, Maximilian Stahl

Blood (2025) 145 (24): 2828–2833.

https://doi.org/10.1182/blood.2024024245

Published: 2025

Journal Articles

Approaching a therapeutic inflection point for FLT3 -mutated AML

Alexander E. Perl

Blood (2025) 145 (24): 2834–2839.

https://doi.org/10.1182/blood.2024024248

Published: 2025

Journal Articles

A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD

Blood (2025) 145 (24): 2857–2872.

https://doi.org/10.1182/blood.2024026581

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysis

Real-world data provide a CARbon copy for ide-cel

Reshaping the TME to enhance checkpoint blockade in ENKTL

Marstacimab Prophylaxis in Hemophilia A/B Without Inhibitors: Results from the Phase 3 BASIS Trial

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera

A controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafil

Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia

Clinical significance of preleukemic somatic GATA1 mutations in children with Down syndrome

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Beyond genotype: challenges in predicting disease risk for carriers of biallelic perforin variants

Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study

Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia

TP53 -mutated acute myeloid leukemia: how can we improve outcomes?

Approaching a therapeutic inflection point for FLT3 -mutated AML

A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only